Neuroprotection and neurorestoration for stroke, TBI and AMD

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture: “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”

September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.: 3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number: 541
Session Time: 10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number: 541.11
Presentation Time: 10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;

October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture: “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”

September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.: 3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number: 541
Session Time: 10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number: 541.11
Presentation Time: 10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;

October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture: “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”

September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.: 3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number: 541
Session Time: 10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number: 541.11
Presentation Time: 10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;

October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

NeuResto Therapeutics

Restoring neuronal function with the brain's own small molecules

The company’s strategy emerged from discoveries of the co-founders that were published in Scientific Reports and Science Advances in 2017. Additionally, see this recent review in Molecular Aspects of Medicine on the mechanisms of Elovanoids and their uses.

NeuResto is developing novel first-in-class therapeutics that promote potent neuroprotection and neurorestoration in order to treat neuronal diseases of the brain and eyes.

NeuResto’s focus is to target large unmet clinical needs in neurologic diseases, such as ischemic stroke, traumatic brain injury (TBI), and wet age-related macular degeneration (wet AMD), for which there are currently few therapeutic options. Additionally, the mechanisms underlying elovanoid's targeting of senescence genes, particular in the retina, are targets for novel therapies in aging diseases of the eye.

NeuResto’s technology is based on the discovery of Elovanoids in the laboratory of co-founder Nicolas Bazan, M.D., Ph.D.